Current Trends in Identifying Rapidly Acting Treatments for Depression.
Dawn F Ionescu, George I Papakostas
Current behavioral neuroscience reports June 1, 2016 DOI: 10.1007/s40473-016-0075-4 via PubMed
Summary
AI-generated from the abstractTraditional antidepressants take weeks to months to work, but ketamine's rapid effects have spurred a decade and a half of research into treatments that act within hours to days, shifting antidepressant drug development. This review highlights recent trends in identifying rapidly-acting antidepressants, discussing ketamine, GLYX-13, nitrous oxide, metabotropic glutamatergic receptor modulators, scopolamine, opioid-receptor modulators, and low field magnetic stimulation.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Ketamine |
| Keywords | Glyx-13 Lfms Experimental therapeutics Kappa-opioid receptor |
| Key finding | The review highlights recent trends in research towards identifying rapidly-acting antidepressants, including ketamine, GLYX-13, nitrous oxide, metabotropic glutamatergic receptor modulators, scopolamine, opioid-receptor modulators, and low field magnetic stimulation. |
Abstract
Traditional antidepressant medications generally take weeks-to-months to achieve effect. However, the breakthrough finding of ketamine's rapidly acting antidepressant properties has inspired a decade-and-a-half of progress towards the identification of treatments that work quickly-within hours-to-days. This paradigm-shift in the discovery of antidepressant therapies has significantly changed the current landscape of antidepressant drug development. Building on this, the current review briefly highlights the recent trends in research towards identifying rapidly-acting antidepressants. Specifically, ketamine, GLYX-13, nitrous oxide, metabotropic glutamatergic receptor modulators, scopolamine, opioid-receptor modulators, and low field magnetic stimulation are discussed.